All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

INT230-6 Alone, With Ipilimumab Induces Positive OS Results in Metastatic Sarcomas

December 30th 2022

INT230-6 demonstrated direct tumor killing in soft tissue sarcoma and elicits an anti-cancer immune response within the injected tumor both alone and in combination with ipilimumab.

Neoadjuvant Immunotherapy Represents an Improved Option for Resectable Melanoma

December 30th 2022

Anna Pavlick, DO, MBA, discusses key updates from clinical trials that continue to shape the treatment of patients with melanoma, the role of immunotherapy in the frontline setting, and the importance of toxicity management and patient support.

The Right Leader in the Right Place at the Right Time

December 30th 2022

Lori J. Pierce, MD harbored a love for science and a general desire to know things, and she was not shy about asking questions. She displayed a gift for math early in life, a trait she and her older sister, Karen, both inherited from their father, Melvin H. Pierce.

Personalized Immunotherapy Regimens Drive Frontline Melanoma Care

December 29th 2022

Claire F. Verschraegen, MD, discusses how nivolumab and ipilimumab fit into the treatment paradigm, poses examples of when treatment-related adverse effects might influence which agents to use, and emphasizes the importance of considering the benefits of immunotherapy.

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29th 2022

Moderately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from the single-arm, phase 2 trial HYPORT-STS.

Physicians Turn to Molecular Profiling to Drive Treatment Decisions in Endometrial Cancer

December 29th 2022

Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.

The Desire to Always Do More

December 29th 2022

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

CA-125 May Be the Key to Renal Medullary Carcinoma Treatment

December 28th 2022

Investigators may have discovered a key detail about renal medullary carcinoma that could have significant ramifications for patients.

INV-1120 Proves Tolerable in Advanced Solid Tumors, Moves to Expansion in Combination With Pembrolizumab

December 28th 2022

Treatment with INV-1120 was well tolerated and demonstrated preliminary signals of stable disease as a single agent in patients with advanced solid tumors.

Researchers Advance a Novel Screening Test for Early-Stage Ovarian and Endometrial Cancer

December 28th 2022

Peter Dottino, MD, FACOG, discusses the need for more accurate early screening tests for ovarian cancer, why testing for early-stage endometrial cancer is also important, the process used to develop the screening test, and how it could be implemented into practice if it is approved by the FDA.

A “Crazy” Idea Leads to a Revolution in Prostate Cancer Care

December 28th 2022

An unshakeable belief in the power of the immune system and a deep-seated desire to make the world a better place have guided Eric J. Small, MD, throughout his career.

Prior Authorization Hurdles Delay Oncology Care

December 27th 2022

Prior authorization on cancer treatments is delaying patient care, affecting outcomes, and diverting providers from patient care according to results of a survey conducted by the Association for Clinical Oncology.

Triplet Combinations Could Represent Next Frontier in Frontline Metastatic RCC

December 27th 2022

Michael R. Harrison, MD, discusses the key long-term data of select doublet combinations in renal cell carcinoma, the early investigation of triplet therapy in the frontline setting, and more.

Immunotherapy and Targeted Therapy May Represent the Future of Later-line Lung Cancer Treatment

December 27th 2022

Konstantinos Leventakos, MD, PhD, discusses the emergence of immunotherapy and lurbinectedin as beneficial treatments in small cell lung cancer, where osimertinib fits into the non–small cell lung cancer treatment paradigm, and more.

Leading The Field of Rare Ovarian Cancers to New Heights

December 27th 2022

During his career, David M. Gershenson, MD, has helped turn ovarian cancer treatment into an evidence-based field and built better therapies through an improved biological understanding of the disease.

DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer

December 26th 2022

Patient history and disease characteristics did not affect outcomes for patients with metastatic HER2-low breast cancer who received fam-trastuzumab deruxtecan-nxki in the DESTINY-Breast04 study.

LP-284 Exhibits Preclinical Efficacy in DDR-Deficient MCL

December 26th 2022

LP-284 showed superior antitumor activity compared with LP-184 independent of PTGR1 expression levels in DNA damage repair–deficient mantle cell lymphoma cell lines.

Approval of Mirvetuximab Soravtansine Provides Support for ADCs in the Ovarian Cancer Treatment Paradigm

December 26th 2022

Caroline Billingsley, MD, discusses the effect of mirvetuximab soravtansine’s approval on the treatment landscape in ovarian cancer and avenues for future research with antibody-drug conjugates and immunotherapy in this space.

DiPersio’s Altered Career Path Led to Groundbreaking Developments in Leukemia

December 26th 2022

A teenage injury cost him a career among the stars, so John F. DiPersio, MD, PhD, became a star hematologist/oncologist instead.

Randall Highlights Advances in Reconstruction Techniques for Patients With Bone Sarcomas

December 25th 2022

Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.